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Abstract Over the last 20 years, productivity in the
pharmaceutical industry has been diminishing because of
constantly increasing costs while output has overall been
stagnant. Despite many efforts, productivity remains a
challenge within the industry. At the same time, healthcare
providers quite rightly require better value for money and
clear evidence that new drugs are better than the current
standard of care, making a complex situation even more
complex. With the implementation of ‘Big Data’ initiatives
trying to integrate data from disparate data sources and
disciplines that are available in life science, the industry
has identified a new frontier that might provide the insights
needed to turn the ship around and allow the industry to
return to sustainable growth.
Key Points
In order to reinvigorate the pharmaceutical drug
pipeline, companies need to take better advantage of
the available data.
‘Big Data’ relates to large data sets that are highly
complex. Data complexity is the key challenge in
implementing Big Data approaches.
Integration of disparate data in the pharmaceutical
industry will help to identify and validate new drug
targets, support early identification of safety and
efficacy issues, and improve patient stratification.
1 Introduction
Do we need ‘Big Data’ in R&D and, if so, how can it help
to overcome the challenges currently facing R&D pro-
ductivity? It is undeniable that pharmaceutical R&D, as the
engine of the pharmaceutical industry, has not been run-
ning smoothly over the last two decades. The approval of
new molecular entities (NMEs)—products that are based
on small chemical molecules or biologics, without a pre-
vious marketing authorization for a particular indication—
has been more or less flat over the last two decades. The
cost of bringing these medicines to market has been con-
stantly rising over the same time period. More worrying,
though, is the fact that the revenue anticipated from these
new medicines is not going to make up for the shortfall
created by recent patent expirations. This is putting the
profitability of many companies at risk, making the current
situation not sustainable [1].
This so-called innovation gap can be attributed to sev-
eral internal challenges. Many promising drug candidates
fail in phase II and phase III—later stages of the clinical
development process [2]. These high attrition rates at a
time when projects have already incurred high costs make
for very expensive failures. Identification of new safety
concerns or issues with the efficacy of the drug at this late
stage results in an unfavourable risk/benefit relationship,
thus rendering these projects commercially not viable.
Moreover, the complexity of the clinical development
process is constantly increasing with the implementation of
new procedures. The Tufts Center for the Study of Drug
Development showed that the overall execution burden
grew by 54 % in the period 2004–2007 compared to the
period 2000–2003 [3].
At the same time, there is also increasing external
pressure on pharmaceutical companies. To start with,
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patents for some of the best-selling drugs have recently
expired, thus threatening the ability for sustained growth
[4]. This is coupled with a changing therapeutic landscape
to address clear unmet medical needs, resulting in projects
with a lower probability of success [5]. This also means
that most low-hanging fruits have been picked, particularly
in those therapeutic areas that the industry has focused on
in the last decade [6]. Increasing regulatory hurdles are also
not helping the problem, although the impact on drug de-
velopment is not entirely clear [7]. Moreover, regulatory
approval is nowadays not enough, as the healthcare sector
is moving away from a fee-for-service model to a value-
based model through health technology assessments—for
instance, by the National Institute for Health and Care
Excellence in the UK or the Institute for Quality and Ef-
ficiency in Health Care in Germany. Pharmaceutical
companies have to provide real-world evidence that new
drugs that come on the market are better than existing
therapies or the competition in order to get reimbursed.
Productivity is therefore no longer just a function of R&D
efficiency; it is also a function of R&D effectiveness [1].
The industry has looked at many ways to stem the de-
cline in productivity, starting with increased R&D spend-
ing, followed by major consolidations, in-licensing,
acquisitions and R&D reorganization—but to no avail [6].
Looking at all of these factors, it becomes evident that
the root cause actually lies somewhere else: lack of data or
lack of appropriate analysis of the available data. High
attrition rates in late-stage clinical trials could, for instance,
be avoided if the relevant information was available earlier
or if the available information could provide clues as to
whether a drug will actually perform as expected in clinical
practice. The probability of success of current projects
within complex therapeutic areas could be increased
through better understanding of the underlying disease
mechanism. In particular, the understanding of real-world
effectiveness is tied to better insights into market require-
ments and real-world performance.
This review provides an overview of how Big Data and
Big Data initiatives can advance the clinical development
process to improve productivity in the pharmaceutical
industry.
2 Big Data
The definition of Big Data is most often associated with the
‘3 V’s’ provided by Gartner [8]. Big Data involves high-
volume, high-velocity and high-variety information assets,
which require new forms of processing to enable enhanced
decision-making, insight discovery and process optimiza-
tion. In particular, in the context of pharmaceutical R&D,
two other dimensions are highly relevant—namely,
veracity and variability. Obviously, the Big Data move-
ment is possible only because of the incredible advances in
information technology (IT) and the different ways in
which information and data can be captured.
The most interesting dimension, but also the most chal-
lenging, is variety. There are many different types of data
that are highly relevant. When it comes to understanding
disease mechanisms and drug discovery, the main focus has
been on genomic data. Since the publication of the first
human genome in 2004, the cost of sequencing has greatly
gone down because of the establishment of new techniques.
Several human genome reference projects have been laun-
ched, such as the 1000 Genomes Project [9] or the 100,000
Genomes Project [10]. These projects will make genetic
information—together with other phenotypic as well as
medical information—available to help and identify new
drug targets by linking particular genes and their products to
individual diseases. This is greatly aided by the availability
of existing genome-wide association studies looking at
single nucleotide polymorphisms (SNPs), insertions and
deletions, as well as more pronounced rearrangements and
their association with different diseases [10–13].
In recent years, data from other sources have been re-
ceiving more and more attention. In addition to genomic
data, other -omics data have moved into the spotlight.
Proteomics and metabolomics, as well as epigenetics and
an integrated view of all of these disciplines, are gaining
more and more traction. Also, the impact of lifestyle
choices is now starting to be factored in.
On the other end of the value chain, electronic health
records and other patient-related information in registries,
hospital administration databases and payer databases are
the focus of interest to establish real-world evidence for the
effectiveness and the value of a particular medicine. For
instance, Pfizer conducted a cohort study using the Health
Improvement Network database in the UK to establish
whether switching patients from atorvastatin (Lipitor) to
simvastatin has a negative effect [14]. Sanofi undertook a
similar approach with its diabetes drug Lantus to establish
that Lantus was not associated with an increased risk of
cancer [15] after it was rejected by the German health
authority [16]. In 2011, AstraZeneca partnered with
Healthcore, the analytics arm of WellPoint, to establish a
partnership to conduct research, which will include
prospective and retrospective observational studies on
disease states, as well as comparative effectiveness re-
search. It will analyse how medicines and treatments al-
ready on the market are working in a number of disease
areas, with a special emphasis on chronic illnesses. It will
also provide insight into the types of new therapies most
needed for treating and preventing disease [17].
With the advent of personalized medicine, the patient is
moving more and more into the spotlight. Increasing
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importance is being put on patient-reported outcomes, in-
cluding those posted on social media such as Twitter,
Facebook and patient forums. With technological ad-
vances, the use of automated sensors and smart devices is
becoming more and more prevalent. In particular, smart-
phones are becoming point-of-care diagnostic tools through
the development of new healthcare-related apps, as well as
add-on diagnostic sensors that use the smartphone as an
enabling platform.
In addition to these external resources, pharmaceutical
companies have a vast array of internal data, ranging from
basic laboratory research to elaborate clinical trial pro-
grammes, which have not been fully analysed and sit idle
in corporate data silos. Several organizations are now
starting to make some of their clinical data available to
outside researchers for further analysis. Project Data
Sphere (http://www.projectdatasphere.org), for instance, is
aimed at making historic phase III comparator arm cancer
data and analytic tools broadly available [18], while several
large pharmaceutical companies have joined forces and
made their data available to interested researchers via
http://clinicalstudydatarequest.com [19]. Other initiatives
include an agreement between Johnson & Johnson and the
Yale School of Medicine to provide a mechanism to make
clinical trial data more widely available [20].
Another element that is often highlighted is velocity.
Velocity refers not only to the ability to access data quickly
but also to how fast data change over time and new in-
formation becomes available. While real-time access is not
critical—at least not in the context of gaining insight into
disease mechanisms or better clinical trials and better
treatment options—the notion of change is clearly relevant.
Topics need to be regularly revisited to evaluate any
changes in the available data that might lead to new in-
sights and inform new knowledge.
From an R&D perspective, veracity or data quality is
also very important. Nevertheless, for most of the data
sources currently in use, there are mechanisms in place to
ensure quality standards, which will benefit even further
through better use of the available data. At the same time,
the introduction of patient-reported outcomes (including
those posted on social media), as well as self-service di-
agnostics, will require a more careful approach and prob-
ably will require further validation through more
conservative channels.
3 Big Data Challenges
The main challenges the industry is facing are associated
with the variety of data. First of all, no single organization
or company has all of these data available. It is therefore
important for companies, the healthcare system and also
the academic community to work together. This has been
recognized, and many pre-competitive or non-competitive
collaborations are taking shape [21].
While excellent systems exist to analyse different data
types in isolation, real value can be gained from integrating
the data into one harmonized, unified knowledge base.
However, this is where the issues begin. Different data
types are stored in different data sources, and these data
sources are not necessarily compatible. Data can be
structured (as in clinical trial management systems or
electronic data capture systems) or completely unstructured
(such as free-text documents or patient-reported outcomes
posted on social media). Even if the data are structured, the
structure of one data source is not necessarily compatible
with that of another data source. Another big challenge is
the use of different terminologies and taxonomies. For
instance, ALT and ALAT both refer to ‘alanine amino-
transferase’—or is it ‘alanine transaminase’? Do we talk
about ‘gender’ or ‘sex’?
In order for disparate data sources to be consolidated
and integrated into a single view of the world, it is im-
portant that they are harmonized into a single data frame-
work. Unfortunately, there are several standards in use.
While the life science community is now focusing on
CDISC (Clinical Data Interchange Standards Consortium)
and MedDRA (Medical Dictionary for Regulatory Ac-
tivities), healthcare systems are more inclined to use
Snomed CT (Systematized Nomenclature of Medicine—
Clinical Terms), HL7 (Health Level 7, a set of international
standards for transfer of clinical and administrative data
between hospital information systems), LOINC (Logical
Observation Identifiers Names and Codes, a universal
standard for identifying medical laboratory observations)
and ICD 9 or 10 (International Classification of Diseases
Version 9 or 10). Efforts are therefore needed to establish
semantic interoperability between these standards or to
create a system that can absorb all of these standards into a
single common format. The advantage of the latter would
be that all other standards would be mapped to the common
format. This would alleviate the fact of having to map all
standards to all other standards [22].
4 Big Data Information Model
While the information in these disparate data sources and
types is certainly heterogeneous, it is also clear that it is all
intrinsically connected as it is related to the knowledge
domain of medicine. In this respect, this information can be
considered to be a large-scale knowledge network of in-
terconnected information units, somewhat akin to the se-
mantic web. Key to the semantic web is the linking of
information through meaningful relationships. These
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relationships are described in the Resource Description
Framework (RDF) through so-called triples—simple sen-
tences composed of a subject, predicate and object, with
the subject and object being linked through the relationship
expressed in the predicate. In order to overcome the chal-
lenge of different terminologies and data structures, the
semantic web also introduces the concept of ontology—
basically, a structured, well defined framework that models
the underlying concepts and relationships explicitly.
Medical information lends itself to such an ontology-based
approach, and the use of semantic web technology in life
science has been well documented [23]. An information
model taking advantage of linked information can be
simplified by enclosing relevant information pertaining to
the same event in a self-contained information unit, pro-
viding all necessary information to understand this indi-
vidual event and linking these self-contained information
units instead [22].
5 Data Analytics
Gaining insight from Big Data is all about relevance and
context. Therefore, any Big Data analytics project needs to
start with a clear question. In this respect, Big Data
analytics is like finding a needle in a haystack. In order to
have any chance of finding this needle, it is important that
you know exactly what this needle looks like. Once rele-
vant data have been identified, the next step is to develop
and apply the right analytical methods and models, so that
the right conclusions can be drawn from the data in the
context of the original question. Since the ever-increasing
flood of different data types makes the identification of
relevant data increasingly difficult, this is an iterative
process where each previous iteration will inform future
evaluations.
Data visualization is an important aspect in dealing with
data analytics. The old saying ‘‘A picture is worth a
thousand words’’ clearly applies. Big Data analytics—or
any data analytics, for that matter—is about understanding
trends, correlations and patterns. As with data standards,
there are also initiatives to standardize some of these vi-
sualizations to provide a good foundation.
In order to achieve meaningful insights and identify
actionable results, data analytics also needs to move from
descriptive business intelligence models to predictive
models and ultimately to prescriptive models. Descriptive
models are purely aimed at analysing what happened in the
past and giving you a good understanding of what was.
Predictive models add another layer to this and try to gain
insights into how these data might help you to better un-
derstand what will happen in the future. Predictive models
are trying to provide insights into potential future states.
Prescriptive data analytics adds again another layer that
aims to provide recommendations on how to proceed,
providing true decision support.
The best example of the development of predictive
models is the research into biological markers (biomarkers)
and the advent of personalized medicine.
Biomarkers are surrogate markers that can be objec-
tively measured and evaluated as indicators of disease
susceptibility and progression, safety concerns and
therapeutic outcome [24]. Biomarkers can be anything
from blood pressure to increasingly complex networks of
individual traits [25, 26]. In the context of pharmaceutical
R&D, biomarkers can help in the validation of disease
targets and identification of suitable patient populations for
the development programme, as well as providing early
signs of safety issues and efficacy in order to facilitate ‘go/
no-go’ decisions. The use of biomarkers in the develop-
ment stage can also provide early indications of real-world
effectiveness, which will be helpful for evaluation of the
commercial viability of a drug early on.
Biomarkers are essential for personalized medicine. In
recent years, it has become evident that developing new
medicines cannot rely on the ‘one size fits all’ approach.
Patient stratification is becoming a prerequisite not only in
the real world but also in the design of successful devel-
opment programmes.
In the field of prescriptive analytics, there are also
projects underway looking at machine learning. For in-
stance, the Memorial Sloan Kettering Cancer Center is
working together with IBM to train the latest supercom-
puter, Watson, to support doctors in making better treat-
ment decisions [27].
6 Big Data and Knowledge Management
In addition to having the capability to gain appropriate
insight from Big Data, it is also vital to communicate these
insights within the company. Companies must devise ap-
propriate knowledge management strategies that enable the
company to maximize the value of their Big Data initia-
tives. A survey by the Economist Intelligence Unit indi-
cates that 41 % of pharmaceutical executives see
knowledge management as one of the main drivers in
productivity gains [28]. It is also clear that managerial
ability and culture have a major impact on how Big Data
initiatives fare [29].
Knowledge management can be divided into three areas:
knowledge creation or research; knowledge utilization or
new product development; and knowledge transfer or col-
laboration [30]. Depending on the primary aim of the Big
Data initiative, different systems need to be put in place to
support these initiatives appropriately. If the primary
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objective is the discovery of new drugs, then companies
need to look at implementing a personalization strategy
that primarily aims to bring people together. Knowledge
and information need to be shared in order to inform in-
dividuals about the latest advances. The goal is to create
embedded knowledge. On the other hand, drug develop-
ment needs to implement a codification strategy that allows
many people to search for and retrieve codified knowledge
from a repository without having to trace and interact with
the source of knowledge. From an IT perspective, the
personalization strategy requires implementation of highly
bespoke systems, whereas the codification strategy requires
systems that are optimized for data storage and retrieval.
7 Big Data Impact
While Big Data has been around for some time, and data
sets in the pharmaceutical industry have always been
complex, it is only now that all of the capabilities associ-
ated with Big Data analytics are slowly falling into place.
The biggest leap to date has been seen in the Health Eco-
nomics and Outcome Research arena, as the examples of
Pfizer and Sanofi show [14, 15]. This can be attributed
partly to the fact that a lot of the available data are more
transactional in nature and therefore are easier to analyse;
partly to the fact that marketing and sales departments have
always been more ‘customer focused’; and partly to the
fact that health information systems and payer systems are
now in place that allow for seamless gathering and inte-
gration of this information.
In the field of drug discovery, well established systems
for the analysis of genomic data are now joined by systems
evaluating the whole systems biology sphere [31].
In clinical development, Big Data is starting to make an
impact, particularly in relation to patient stratification and
recruitment. Evaluation of the available patient information
can support the modelling of inclusion/exclusion criteria, as
well as helping with the identification of suitable patients.
Moreover, the establishment of integrated systems pro-
viding centralized access to all available data is helping with
the conduct of clinical trials—in particular, risk-based
monitoring. The ability to compare and analyse information
gathered from all clinical trial sites in a centralized setting
allows companies to better evaluate safety issues, operational
shortfalls and outright fraud by individual sites [32].
8 Conclusion
The pharmaceutical industry is only starting to implement
Big Data initiatives, and a long road still lies ahead. Nev-
ertheless, the industry has realized that it needs to focus on
its main assets: its own data and the other available data.
This will assist us to understand disease mechanisms better,
define true unmet medical needs and deliver better
medicines at affordable prices to an increasingly stretched
healthcare system, ultimately helping those who need it
most: the patients.
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